Literature DB >> 10590068

The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.

R Salgia1, E Quackenbush, J Lin, N Souchkova, M Sattler, D S Ewaniuk, K M Klucher, G Q Daley, S K Kraeft, R Sackstein, E P Alyea, U H von Andrian, L B Chen, J C Gutierrez-Ramos, A M Pendergast, J D Griffin.   

Abstract

The chemokine stromal-derived factor-1alpha (SDF-1alpha) is a chemoattractant for CD34(+) progenitor cells, in vitro and in vivo. The receptor for SDF-1alpha, CXCR-4, is a 7 transmembrane domain receptor, which is also a coreceptor for human immunodeficiency virus (HIV). Here we show that transformation of hematopoietic cell lines by BCR/ABL significantly impairs their response to SDF-1alpha. Three different hematopoietic cell lines, Ba/F3, 32Dcl3, and Mo7e, were found to express CXCR-4 and to respond to SDF-1alpha with increased migration in a transwell assay. In contrast, after transformation by the BCR/ABL oncogene, the chemotactic response to SDF-1alpha was reduced in all 3 lines. This effect was directly due to BCR/ABL, because Ba/F3 cells, in which the expression of BCR/ABL could be regulated by a tetracycline-inducible promoter, also had reduced chemotaxis to SDF-1alpha when BCR/ABL was induced. The reduced response to SDF-1alpha was not due to an inability of BCR/ABL-transformed cell lines to migrate in general, as spontaneous motility of BCR/ABL-transformed cells was increased. In mice, injection of SDF-1alpha into the spleen resulted in a transient accumulation of untransformed Ba/F3 cells, but not Ba/F3. p210(BCR/ABL) cells administered simultaneously. The mechanism may involve inhibition of CXCR-4 receptor function, because in BCR/ABL-transformed cells, CXCR-4 receptors were expressed on the cell surface, but SDF-1alpha calcium flux was inhibited. Because SDF-1alpha and CXCR-4 are felt to be involved in progenitor cell homing to marrow, the abnormality decribed here could contribute to the homing and retention defects typical of immature myeloid cells in chronic myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590068

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.

Authors:  Weidong Yu; Xiaolin Sun; Hongxing Tang; Yunxia Tao; Zonghan Dai
Journal:  Leuk Lymphoma       Date:  2010-06

2.  Chronic myeloid leukemia: the basis of treatment for tomorrow.

Authors:  Angelo M Carella; John M Goldman; Giovanni Martinelli; Junia V Melo; Danilo Perrotti
Journal:  Haematologica       Date:  2011-12       Impact factor: 9.941

Review 3.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

Review 4.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 5.  The bone marrow microenvironment and leukemia: biology and therapeutic targeting.

Authors:  Edward Allan R Sison; Patrick Brown
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

6.  Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.

Authors:  Daniela S Krause; Katherine Lazarides; Juliana B Lewis; Ulrich H von Andrian; Richard A Van Etten
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

7.  Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway.

Authors:  Yingzhu Li; Nancy Clough; Xiaolin Sun; Weidong Yu; Brian L Abbott; Christopher J Hogan; Zonghan Dai
Journal:  J Cell Sci       Date:  2007-03-27       Impact factor: 5.285

8.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

9.  Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

Authors:  Anupriya Agarwal; Angela G Fleischman; Curtis L Petersen; Ryan MacKenzie; Samuel Luty; Marc Loriaux; Brian J Druker; Randall L Woltjer; Michael W Deininger
Journal:  Blood       Date:  2012-08-13       Impact factor: 22.113

10.  BCR-ABL1 alters SDF-1alpha-mediated adhesive responses through the beta2 integrin LFA-1 in leukemia cells.

Authors:  Ying-Yu Chen; Mobeen Malik; Brian E Tomkowicz; Ronald G Collman; Andrzej Ptasznik
Journal:  Blood       Date:  2008-03-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.